Skip to content
Search

Latest Stories

Follow Us:
Top Stories

Generative AI Can Save Lives: Two Diverging Paths In Medicine

Opinion

Doctor using AI technology
Akarapong Chairean/Getty Images

Generative AI is advancing at breakneck speed. Already, it’s outperforming doctors on national medical exams and in making difficult diagnoses. Microsoft recently reported that its latest AI system correctly diagnosed complex medical cases 85.5% of the time, compared to just 20% for physicians. OpenAI’s newly released GPT-5 model goes further still, delivering its most accurate and responsive performance yet on health-related queries.

As GenAI tools double in power annually, two distinct approaches are emerging for how they might help patients.


One path involves FDA-approved tools built by startups and established technology companies. The other empowers patients to safely use existing tools like ChatGPT, Gemini, and Claude.

Each path has advantages and tradeoffs. Both are likely to shape healthcare’s future.

To better understand what’s at stake, it’s first helpful to examine how generative AI differs from the FDA-approved technologies used in medicine today.

Narrow AI

Medicine has relied on “narrow AI” applications for more than two decades, using models trained to complete specific tasks with structured clinical data.

These tools are programmed to compare two data sets, identify subtle differences, and assign a precise probability factor to each. In radiology, for example, narrow AI models have been trained on thousands of mammograms to distinguish between those demonstrating early-stage breast cancer and those with benign conditions like fibrocystic disease. These tools can detect differences too subtle for the human eye, resulting in up to 20% greater diagnostic accuracy than doctors working alone.

Because narrow AI systems produce consistent, repeatable results, they fit neatly within the FDA’s current regulatory framework. Approval requires measurable data quality, algorithmic transparency, and reproducibility of outcomes.

Generative AI: A new kind of medical expertise

Generative AI models are built differently. Rather than being trained on structured datasets for specific tasks, they learn from the near-totality of internet-accessible content, including thousands of medical textbooks, academic journals, and real-world clinical data.

This breadth allows GenAI tools to answer virtually any medical question. But the large language model responses vary based on how users frame questions, prompt the model, and follow up for clarification. That variability makes it impossible for the FDA to evaluate the accuracy and quality of the tools.

Two distinct pathways are emerging to bring generative AI into clinical practice. Maximizing their impact will require the government to change how it evaluates and supports technological innovation.

1. The traditional path: FDA-approved, venture-backed

As medical costs rise and patient outcomes stagnate, private technology companies are racing to develop FDA-approved generative AI tools that can help with diagnosis, treatment, and disease management.

This approach mirrors the narrow AI model: high-priced tools that are highly regulated and largely dependent on insurance coverage for American families to afford them.

With venture funding, companies can fine-tune open-source foundation models (like DeepSeek or Meta’s LLaMA) using a process called “distillation.” This involves extracting domain-specific knowledge and retraining the model with real-world clinical experiences, such as tens of thousands of X-rays (including radiologists’ readings) or anonymized transcripts of patient-provider conversations.

Consider how this approach might impact diabetes management. Today, fewer than half of patients achieve adequate disease control. The consequences include hundreds of thousands of preventable heart attacks, kidney failures, and limb amputations each year. A generative AI tool trained specifically for diabetes could replicate the approach of a skilled chronic disease nurse: asking the right questions, interpreting patient data, and offering personalized guidance to help users better manage their blood sugar levels.

This path already appears to have federal backing. The Trump administration recently launched its Medicare-funded Health Tech Ecosystem initiative, partnering with more than 60 tech and healthcare firms to pilot AI-enabled tools for chronic disease management, including diabetes and obesity.

Although distillation is faster and cheaper than building an AI model from scratch, the timeline to FDA approval could still span several years and cost tens of millions of dollars. And any adverse outcome could expose companies to legal liability.

2. The alternate path: Empowering patients with GenAI expertise

This second model flips the innovation equation. Instead of relying on expensive, FDA-approved tools developed by private tech companies, it empowers patients to use low-cost, publicly available generative AI to manage their own health better. This can be accomplished through digital walkthroughs, printed guides, YouTube videos, or brief in-person sessions.

For example, a patient might input their blood pressure, glucose readings, or new symptoms and receive reliable, evidence-based advice from ChatGPT or Claude: whether a medication change is needed, when to alert their doctor, or if emergency care is warranted. Similarly, patients working with their physicians could use these LLMs to detect early signs of post-operative infection, worsening heart failure, or neurological decline.

With 40% of doctors already engaged in “gig work,” an ample supply of clinicians from every specialty would be available to contribute their expertise to develop these training tools.

This model would bypass the need for costly product development or FDA approval. And because it offers education, not direct medical care. It would create minimal legal liability.

Government support for both models

These approaches are not mutually exclusive. Both have the potential to improve care, reduce costs, and extend access. And both will benefit from targeted government support.

The traditional path will require companies to evaluate the reliability of their tools by testing the accuracy of their recommendations against clinicians. When these tools are equivalent, the FDA would give its approval.

The alternate path of educating patients to use existing large language models will benefit from educational grants and added expertise from agencies like the CDC and NIH, partnering with medical societies to develop, test, and distribute training materials. These public-private efforts would equip patients with the knowledge to use GenAI safely and effectively without waiting years for new products or approvals.

Together, these models offer a safer and more affordable future for American healthcare.

Robert Pearl, the author of “ChatGPT, MD,” teaches at both the Stanford University School of Medicine and the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.


Read More

Written on a whiteboard: AI?
The letters AI and a question mark written in black marker on a whiteboard

A Democracy That Uses AI Agents Needs Permission Receipts

An organization can correct a faulty AI-generated paragraph in minutes. Repairing the damage after an automated system impersonates a trusted source, emails thousands of people, or changes public records can take much longer. As AI tools gain permission to act, civic institutions need to govern the authority they delegate with the same seriousness they give to the accuracy of an answer.

On October 8, OpenAI reported disrupting covert influence operations linked to Iran and Russia. One operation used seven fabricated journalist identities to place material in outside publications. OpenAI investigators identified almost 100 articles published or syndicated under those bylines across roughly a dozen outlets. The operators were humans using AI to refine articles and pitches. That distinction matters: this was deceptive human direction amplified by technology, rather than evidence of independent machine intentions.

Keep ReadingShow less
classroom, learning, teaching, class, students

AI literacy isn’t just about jobs. Learn why schools should teach students to question AI outputs, verify claims, and think critically as citizens.

Getty Images, Rafa Fernandez Torres

AI Is Shaping Democracy. Are We Preparing Students?

Almost everyone I know is talking about artificial intelligence. Teacher friends say it helps with administrative tasks, then describe their frustration when students use it to complete assignments. Principals wonder whether teachers are using it effectively. Colleagues past and present worry about how it will shape their students’ lives. And among parents in my kids’ circles, the chatter is mostly about jobs: Do we need AI literacy to stay relevant at work? What does AI mean for our children’s future careers? How much should we trust it?

These questions matter, but I worry we’re missing the plot. AI literacy isn’t only about preparing students to work with AI. It’s about preparing them to live in a democracy increasingly shaped by it.

Keep ReadingShow less
Judge's Gavel Hammer as a Symbol of Law and Order with Processor CPU AI Chip.

Anthropic warns of AI botnets seizing the web. A veteran trial attorney argues the solution is simple: unplug the internet and bring back an analog society.

Getty Images, Alexander Sikov

Let the Bots Have the Internet!

Anthropic CEO Dario Amodei has warned "that a swarm of AI agents soon ‘could be capable of taking over the entire internet with a persistent botnet.’”

Oh, perish the thought! I say, let’s unplug from and discontinue use of the internet. Let the bots roam uselessly on an unused internet and perhaps die a natural death there!

Keep ReadingShow less
Illustration of a man and woman arguing

Arguments or debates, disputes or conflicts, verbal clashes. Angry men and women roar at each other

Getty Images

What If Polarization Is the Wrong Diagnosis?

I just listened to political scientist Lilliana Mason challenge one of the most familiar explanations of what is wrong with American politics.

We are constantly told that America suffers from polarization. Republicans and Democrats have moved too far apart. They distrust each other, increasingly regard one another as enemies, and have lost the ability to compromise. The prescribed remedies are familiar: more civility, more dialogue, less hostility, and a return to the political center.

Keep ReadingShow less